With the withdrawal of COX-2 inhibitors, opioids are an obvious alternative choice for pain

Rob Hutchison, PharmD

doi:10.5055/jom.2005.0006

Authors

Rob Hutchison, PharmD

DOI:

https://doi.org/10.5055/jom.2005.0006

Keywords:

-

Abstract

-

Author Biography

Rob Hutchison, PharmD

clinical pharmacy specialist in pain management at Presbyterian Hospital of Dallas and an assistant professor at Texas Tech University Health Sciences Center School of Pharmacy, in Dallas, Texas. Contact author: robhutchison@texashealth.org

References

Merck & Co., Inc.: Merck announces voluntary worldwide withdrawal of VIOXX® [press release]. Merck & Co., Inc. Web site. Available at www.merck.com/newsroom/press_releases/product/2004_0930.html. Accessed December 4, 2004.

Topol EJ: Failing the public health: Rofecoxib, Merck, and the FDA. N Engl J Med. 2004; 351(17): 1707-1709.

Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naprosyn in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21): 1580-1588.

US Food and Drug Administration: Public Health Advisory rec-ommending limited use of COX-2 inhibitors. FDA web site. Available at www.fda.gov/bbs/topics/answers/2004/ANS01336.html. Accessed December 28, 2004.

Juni P, Nartey L, Reichenbach S, et al.: Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet. 2004; 364(9450): 2021-2029.

Fitzgerald GA: Coxibs and cardiovascular disease. N Engl J Med. 2004; 351(17): 1709-1711.

Clark WJ, Layton D, Shakir SA: Do some inhibitors of COX-2 increase the risk of thromboembolic events? Drug Saf 2004; 27(7): 427-456.

US Food and Drug Administration: Questions and answers: Strengthened warnings on Bextra. FDA Web site. Available at www.fda.gov/cder/drug/infopage/bextra/bextraQA.htm. Accessed December 17, 2004.

Kurella M, Bennett WM, Chertow GM: Analgesia in patients with ESRD: A review of available evidence. Am J Kidney Dis. 2003; 42(2): 217-228.

Schnitzer TJ, Burmester GR, Mysler E, et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet. 2004; 364(9435): 665-674.

White WB, Strand V, Roberts R, et al.: Effects of the cyclo-oxygenase-2 specific inhibitor valdecoxib versus nonsteroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther. 2004; 11(4): 244-250.